BPC-157 Dosage: What the Research Suggests
If you've landed here, you probably already know what BPC-157 is. You've read about the injury repair research, the gut-healing data, maybe the tendon and ligament studies. Now you're asking the next logical question: how much, how often, and how?
That's a reasonable place to be — and it's a harder question to answer cleanly than most corners of the internet will admit. Let me walk through what the research actually shows, where the gaps are, and why BPC-157 dosage isn't as simple as copying a number from a forum post.
What Animal Research Shows About BPC-157 Dosage
The overwhelming majority of BPC-157 research has been conducted in rodent models. That's important context for everything that follows. The dosing ranges in these studies are well-documented, and they're what most protocol discussions ultimately trace back to — whether or not the person citing them acknowledges it.
In rodent studies, BPC-157 has been used across a fairly wide range: roughly 1–10 mcg/kg of body weight for subcutaneous or intraperitoneal injection protocols, with some studies going as high as 100 mcg/kg without apparent toxicity. The most commonly cited range in healing-focused research tends to cluster in the 2–10 mcg/kg window.
For a 80 kg (175 lb) human, a naive weight-based extrapolation from that range would put you somewhere between 160–800 mcg per dose. Many anecdotal human protocols reference 200–500 mcg per injection, which falls squarely in the middle of that extrapolated range — not because it's been tested in humans at scale, but because it maps onto what was used in animal models.
To be direct: there are no published, peer-reviewed human clinical trials establishing an optimal BPC-157 dosage. The numbers circulating in biohacking communities are informed extrapolations, not confirmed human data. That distinction matters when you're thinking about this seriously.
Subcutaneous vs. Oral Administration: What Changes
The route of administration is one of the more meaningful variables in the BPC-157 conversation, and it affects dosing logic in ways that aren't always spelled out clearly.
Subcutaneous injection is the most common route in animal research and is generally considered to have higher bioavailability than oral delivery for peptides. The peptide is absorbed into systemic circulation more directly, which matters when the research target is systemic or distant from the gut.
Oral administration shows up in a meaningful subset of the BPC-157 research — particularly in gut-healing contexts. Some studies suggest BPC-157 may retain some activity when administered orally, which would be unusual for a peptide (most are degraded by digestive enzymes before reaching systemic circulation). The proposed mechanism involves local action in the GI tract rather than systemic absorption, which is why oral protocols are more frequently discussed in gut-health contexts specifically.
The dosing logic differs between routes. If you're using oral BPC-157 with the goal of local GI effects, the rationale is different than using subcutaneous BPC-157 for systemic tissue repair. Animal research supports both angles, but they're not interchangeable protocols with swapped delivery methods — they're mechanistically different approaches.
Daily vs. Pulsed Frequency
Most animal research uses daily dosing over defined study periods — typically anywhere from one to four weeks. There isn't a clean body of research comparing pulsed or cycling protocols against continuous daily dosing in the way that exists for some other compounds.
In practice, many human protocols based on animal data follow a daily injection approach during an active protocol period (often 4–6 weeks), then either stop or cycle off. Some biohackers prefer pulsed protocols (every other day, or a few times per week) on the assumption that cycling reduces receptor adaptation — but this isn't well-supported by BPC-157-specific research. That logic borrows more from other peptide and hormone protocols than from BPC-157 data directly.
The honest answer: the research doesn't give strong guidance on optimal frequency for human use. Daily dosing is what the animal studies used, so it's what most protocols default to.
Why Individual Context Changes Everything
BPC-157 dosage discussions often skip past the fact that the right protocol is highly context-dependent. A few factors that should shape thinking:
Body weight and composition. The animal research is weight-dosed, so body weight is at least a reasonable starting variable — even if the extrapolation has limits.
The target tissue or system. Gut healing, tendon repair, and systemic anti-inflammatory goals may not call for identical protocols. The research context matters.
Baseline health and other compounds. BPC-157 doesn't exist in isolation in most real-world use cases. Interactions with other peptides, medications, or underlying conditions aren't well-characterized.
Individual response variation. Peptides don't hit everyone the same way. What the animal models show is population-level effects at specific doses — individual variation in response is real and meaningful.
For a deeper look at how BPC-157 compares to other tissue-repair peptides and how it's used in context, the BPC-157 research overview covers the mechanistic background, and the TB-500 vs BPC-157 breakdown is worth reading if you're trying to choose between them or understand how they might work together.
What to Look for in Study Methodology
Not all BPC-157 research is created equal, and learning to read the methodology helps you evaluate claims more critically.
Check the route of administration. A study using intraperitoneal injection isn't the same as one using subcutaneous injection, and oral administration data is a different category entirely.
Check the dose and species. Rat data and mouse data use different weight-based dosing. And dose-response relationships may not scale linearly across species.
Check whether effects were local or systemic. Some of the most impressive BPC-157 results in animal models involve local injection near the injury site. Systemic subcutaneous injection and local injection aren't the same intervention.
Check the study duration and design. Short-term acute models tell you something different than chronic multi-week protocols.
Want to go deeper? Peptide 101: The Beginner's Guide covers how peptides work mechanistically, what bioavailability means for different delivery routes, and how to approach research literature critically. $8.99 → /products
This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new health protocol.